RESEARCH MONOGRAPH · KDC-MN-283

Leuprolide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

83/100

The most-studied GnRH agonist in medicine, and still the default for a reason

Leuprolide is the GnRH agonist that became a workhorse. Approved in 1985 as Lupron, it's been used continuously for nearly four decades across prostate cancer, endometriosis, fibroids, central precocious puberty, IVF protocols, and a stack of off-label uses. If you're studying gonadotropin suppression in any model, leuprolide is the reference compound. There's just no real competitor in terms of depth.

The mechanism is standard for the class. Continuous receptor stimulation produces an initial flare (LH and FSH spike), then GnRH receptor downregulation and uncoupling from G-proteins gives you the sustained hypogonadotropic state. What's worth knowing is that the suppression isn't always as complete as the marketing suggests, especially with depot formulations as the dosing interval stretches. The pharmacokinetics of the various Lupron Depot formulations (1-month, 3-month, 4-month, 6-month) are not linearly equivalent, and the trough LH/testosterone can drift up at the end of cycles in a meaningful subset of patients. That's been in the literature for years and it matters for any research using leuprolide as a suppression tool.

What we like: extensive safety database, well-characterized pharmacokinetics, and a clinically meaningful body of work on the flare phase specifically. The Lupron Depot pharmacokinetic modeling that came out of the Abbott/AbbVie groups is genuinely well-done.

What we dont love is the conflation of leuprolide with all the other GnRH agonists in casual research discussions. Leuprolide is a 9-residue peptide (nonapeptide), unlike triptorelin and goserelin which are decapeptides. The structural difference matters for receptor binding kinetics and for some of the off-target observations.

Sourcing is genuinely good. Leuprolide acetate is well-characterized, multiple pharma-scale manufacturers exist, and research-grade material from reputable peptide suppliers typically lands above 98 percent HPLC. The deletion sequence and racemization profile are well-understood failure modes that good QC catches.

Value depends entirely on whether you need the depot or the daily-injection equivalent. The daily form is straightforward research material. The depot formulations are formulation pharmacy work that most research labs dont need.

Honestly, leuprolide is the GnRH agonist we default to when the question is just "can we suppress this axis reliably." The clinical signal is enormous.

Evidence: 95
Mechanism: 92
Reliability: 88
Safety: 80
Sourcing: 82
Value: 68
Signal: 72
Staying power: 88

Plain-language summary Intrigue 60 / 100

Leuprolide (Lupron) is the most-prescribed GnRH analog in the world, mechanistically identical to triptorelin and goserelin: chronic activation of the GnRH receptor desensitizes it and shuts down the entire downstream sex-hormone axis. Approved in 1985 and used for prostate cancer, endometriosis, uterine fibroids, and precocious puberty. The depot formulations come in one-, three-, four-, and six-month versions. The one-to-two-week initial flare can transiently worsen prostate cancer symptoms or trigger seizures in puberty patients, so concurrent androgen-receptor blockers are often given at start. The puberty-suppression use, especially in transgender adolescents, has become culturally and politically contentious. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic GnRH agonist (nonapeptide)

A synthetic GnRH agonist; the most prescribed GnRH analog worldwide; approved for prostate cancer, endometriosis, fibroids, and precocious puberty.

Abstract

Leuprolide (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; CAS 53714-56-0; molecular formula C59H84N16O12; molecular weight 1209.41) is a synthetic GnRH agonist nonapeptide developed at Abbott and approved by the FDA in 1985 under the trade name Lupron. Mechanism is identical to triptorelin: chronic exposure desensitizes pituitary GnRH receptors and suppresses LH/FSH after an initial 1-to-2-week flare. Plasma half-life is approximately 3 hours for the parent peptide; depot formulations release over 1, 3, 4, or 6 months. Leuprolide is the most prescribed GnRH analog globally and is the workhorse of clinical GnRH suppression. Approved indications: prostate cancer, endometriosis, uterine leiomyomata (fibroids), central precocious puberty, IVF protocols, and (recently) delayed puberty in transgender adolescents in some markets. Used as the canonical GnRH agonist in academic endocrine pharmacology and as a pharmacological tool for HPG axis manipulation.

Mechanism of action

GnRH agonist nonapeptide; chronic exposure desensitizes pituitary GnRH receptors and suppresses LH/FSH. Mechanism identical to triptorelin.

Reported research dose ranges

Clinical depot 7.5 mg, 22.5 mg three-monthly, or 30 mg intramuscular or subcutaneous. Rodent studies 0.1 to 1 mg/kg.

References

Crawford ED, et al. A randomized phase III trial of long-acting leuprolide for advanced prostate cancer. Urology 2007.
Plosker GL, Brogden RN. Leuprorelin. Drugs Aging 1994.
Olshan AF, et al. Long-term effects of GnRH analog treatment for central precocious puberty. Hum Reprod Update 2006.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-283

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Leuprolide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs